Miruvor
Sign up
The short answer

What studies of Mirtazapine (Remeron) found

5papers on Mirtazapine (Remeron)
36people in 1 study testing Mirtazapine (Remeron) alone
1randomised trial, the strongest kind of study

At a glance, by condition

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, the placebo trial (very low certainty): 3 findings, all C.

4 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Mirtazapine (Remeron) might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 5 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Mirtazapine (Remeron) · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Symptoms

Depression1 study · 36 people took Mirtazapine (Remeron) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (72 in all).

The placebo trial72 randomised · mirtazapine 24 weeks; CCBT 12 weeks · standard dose 15– 45 mg, allowing lower dose, 24 weeks

Depression improved more than in the comparison group.

The evidence is very uncertain about the effect of mirtazapine (Remeron) on depression in ME/CFS. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (72 in all)
See the 1 study
  1. Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial. (2008)

    People in the study
    72 randomised
    Dose
    standard dose 15– 45 mg, allowing lower dose, 24 weeks
    Outcome
    HRSD score Hamilton Rating Scale for Depression
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
Fatigue1 study · 36 people took Mirtazapine (Remeron) Uncertain –
Moderate certainty

Why this grade: Uncertain, moderate certainty, from randomised trials: few people (72 in all); helped less than ccbt, an active treatment; not a sign of harm.

The placebo trial72 randomised · mirtazapine 24 weeks; CCBT 12 weeks · standard dose 15– 45 mg, allowing lower dose, 24 weeks

Fatigue improved less than with the comparison treatment.

Mirtazapine (Remeron) helped fatigue less than ccbt in the one comparison. Uncertain · moderate certainty –

  • Few people (72 in all)
  • Helped less than ccbt, an active treatment; not a sign of harm
See the 1 study
  1. Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial. (2008)

    People in the study
    72 randomised
    Dose
    standard dose 15– 45 mg, allowing lower dose, 24 weeks
    Outcome
    Fatigue Scale score Fatigue Scale
    Effect
    worse
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low

Daily life and health overall

Overall symptoms1 study · 36 people took Mirtazapine (Remeron) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (72 in all).

The placebo trial72 randomised · mirtazapine 24 weeks; CCBT 12 weeks · standard dose 15– 45 mg, allowing lower dose, 24 weeks

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of mirtazapine (Remeron) on overall symptoms in ME/CFS. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (72 in all)
See the 1 study
  1. Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial. (2008)

    People in the study
    72 randomised
    Dose
    standard dose 15– 45 mg, allowing lower dose, 24 weeks
    Outcome
    Clinical Global Impression Scale Clinical Global Impression
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low
Quality of life1 study · 36 people took Mirtazapine (Remeron) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (72 in all); effect size 0.99 (large).

The placebo trial72 randomised · mirtazapine 24 weeks; CCBT 12 weeks · standard dose 15– 45 mg, allowing lower dose, 24 weeks

Quality of life improved more than in the comparison group.

The evidence is very uncertain about the effect of mirtazapine (Remeron) on quality of life in ME/CFS. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (72 in all)
  • Effect size 0.99 (large)

How big was the difference?

0.99, large. The effect size compares Mirtazapine (Remeron) with placebo.

See the 1 study
  1. Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial. (2008)

    People in the study
    72 randomised
    Dose
    standard dose 15– 45 mg, allowing lower dose, 24 weeks
    Outcome
    SF–36 mental sub-scale 36-item Short Form Health Survey
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low

Side effects

Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Nausea or stomach upset1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    15 mg at the start

  2. 2Raise

    Raised step by step in 1 of 1 studies

  3. 3Top dose

    Most often 45 mg (1 of 1 studies)

Doses across 1 study

15 to 45 mg.

Each study’s dose, as printed

All papers

  1. Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial.2008 · placebo trial · 72 randomised
    Summary

    This three-armed randomised clinical trial included 72 patients with chronic fatigue complaints; 65 of the 72 fulfilled Oxford criteria and 29 fulfilled CDC criteria. Participants were recruited at a specialist clinic, partly by general-practitioner referral and partly by screening. The study compared a comprehensive cognitive–behavioural treatment (CCBT) programme for 12 weeks (two 1.5 h group sessions per week: cognitive–behavioural therapy 1.5 h and body awareness therapy 1.5 h, plus a self-managed exercise programme) with double-blind mirtazapine (standard dose 15–45 mg, allowing lower dose) or inactive placebo. After 12 weeks, treatment continued for another 12 weeks in a mixed crossover–combination design. Primary outcomes were the Fatigue Scale and Clinical Global Impression (CGI); secondary measures included the Hamilton Rating Scale for Depression (HRSD), Subjective Health Complaint inventory (SHC), 36-item Short Form Health Survey (SF–36) and cardiorespiratory fitness. At 12 weeks, the CCBT group showed significant improvement compared with the mirtazapine and placebo groups on the Fatigue Scale (P=0.014) and CGI (P=0.001). At 24 weeks, the group initially receiving CCBT followed by mirtazapine showed significant improvement compared with the placebo-plus-CCBT reference group on the Fatigue Scale (P50.001), CGI (P=0.002), HRSD (P=0.018) and SHC pseudoneurology sub-scale (P=0.011). The SF–36 mental sub-scale showed significant improvement for mirtazapine for 24 weeks plus CCBT for 12 weeks (P=0.045). Secondary outcome measures showed overall improvement with no significant difference between treatment groups. All patients taking mirtazapine and 45% of patients taking placebo reported at least one adverse event. In the mirtazapine group, sedation was 56%, increased appetite 31%, weight increase 33% and restless legs syndrome 19%; in the placebo group, headache 17%, sedation 11%, weight increase 11% and insomnia 11%. Harms withdrawal counts are not reported.

  2. Depression and brain fog as long-COVID mental health consequences: Difficult, complex and partially successful treatment of a 72-year-old patient-A case report.2023 · case report · 1 in the study
    Summary

    This case report describes one 72-year-old female with long COVID after COVID-19 infection, treated in a neurological day hospital and a psychiatric inpatient unit and followed as an outpatient. There was no comparison group. Between June 17 and July 8 2022 she was treated in a neurological day hospital without improvement in her health status. She then received outpatient psychiatric help and antidepressant therapy with sertraline 50 mg per day and mirtazapine 15 mg per day for almost 2 months, without significant improvement in her condition. In the psychiatric inpatient unit, between August 29 and September 23, 2022, she received venlafaxine up to 75 mg per day, trazodone up to 50 mg in the evening, nutritional supplements, enteral feeding, and non-drug therapy (visual art, music, drama, dance and movement therapy, occupational therapy, psychotherapy, physiotherapy). At hospitalization, PHQ-9 was 21 and CGI-S was 6; at discharge PHQ-9 was 8, CGI-S 3, and CGI-I 2. At the last outpatient follow-up visit on 01/5/2023, PHQ-9 was 5, CGI-S 3, and CGI-I 2. Mood, energy, anxiety, and sleep improved, but rapid fatigability, difficulty concentrating, unclear thinking, forgetfulness, and brain fog persisted; weight remained 48 kg with no weight gain, and she remained unable to resume work. Side effects and withdrawals were not reported.

  3. Treating chronic fatigue syndrome - a study into the scientific evidence for pharmacological treatments.2011 · review
    Summary

    The paper reports a questionnaire survey of 94 CFS patients from Queensland and New South Wales, recruited through support groups and newspaper and email advertisements, plus a search for randomised controlled trials. Patients filled out a questionnaire on current medicines and supplements; no treatment was given by the authors, and the survey had no comparison group. The 94 patients used 474 different medicines and supplements. Commonly used were antidepressants (41%), sedatives (27%), B vitamins (47%), magnesium (24%) and co-enzyme Q10 (7%). The search identified 20 RCTs. Findings included no difference for fluoxetine on fatigue or SF-36, no difference between treatment and placebo on individual questionnaires, and no effect for several agents including phenelzine, moclobemide, valaciclovir, terfenadine, melatonin, ginseng, bovine liver extract and a polynutrient supplement. One hydrocortisone trial reported 87% rated themselves improved versus 17% on placebo (p<0.001); another reported 53% vs. 29% (p=0.04) improvement in wellness score. Harm notes included diarrhoea with high-dose oral magnesium, long-term adrenal gland suppression with adrenal hormones, addiction and loss of effectiveness with benzodiazepines and opiates, and hormonal/lipid changes with DHEA. No worsening or stopping was reported. The authors state limitations.

  4. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
    Summary

    This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime